Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial - Takeaways - MDSpire

Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial

  • By

  • Christian S. Hendershot

  • Michael P. Bremmer

  • Michael B. Paladino

  • Georgios Kostantinis

  • Thomas A. Gilmore

  • Neil R. Sullivan

  • Amanda C. Tow

  • Mark A. Prince

  • Sarah S. Dermody

  • Robyn Jordan

  • Sherry A. McKee

  • Paul J. Fletcher

  • Eric D. Claus

  • Klara R. Klein

  • May 26, 2026

  • 0 min

Share

  • 1

    Cigarette smoking causes over 8 million deaths annually and increases risks for cardiovascular diseases, type 2 diabetes, and cancer-related deaths.

  • 2

    GLP-1 receptor agonists, like semaglutide, show promise as a therapeutic option for smoking cessation and may mitigate weight gain post-cessation.

  • 3

    This phase 2a trial evaluated semaglutide monotherapy effects on smoking outcomes in non-treatment-seeking smokers over 9 weeks.

  • 4

    Participants received weekly semaglutide injections, with assessments of cigarette use, craving, withdrawal, and weight throughout the trial.

  • 5

    The study aims to explore the potential of semaglutide to reduce smoking behavior without concurrent smoking cessation interventions.

Original Source(s)

Related Content